Castration Sensitive Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse events were comparable between both groups and no fatalities were reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Short-term androgen deprivation therapy (ADT) with primary adjuvant radiotherapy is known to improve metastasis-free survival in patients

/PRNewswire/ -- DelveInsight's Metastatic Castration-Sensitive Prostate Cancer Market Insights report proffers a detailed comprehension of the Metastatic...

Metastatic Castration-Sensitive Prostate Cancer market dynamics is anticipated to witness a significant growth owing to the rising prevalence of prostate cancer cases due to the rapidly aging

Prostate cancer (PCa) is the third-leading cause of male cancer-associated mortality in Ireland accounting for 11% of all cancer deaths 1

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. 1 Results will be featured in an oral presentation at the American...